Variable | Usual care before vs. during the trial | Usual care pre-trial vs. non-enrolled vs. usual care controls | |||||
---|---|---|---|---|---|---|---|
Pre-trial period (N = 200) | During-trial period (N = 229) | p-value | Pre-trial group (N = 200) | Non-enrolled group (N = 155) | Usual Care control group (N = 74) | p-value | |
Mean Arterial Pressure (MAP) | |||||||
MAP while receiving vasopressors (mean [SD]) | 72.5 (5.1) | 72.4 (5) | 0.76 | 72.5 (5.1) | 72.3 (5.1) | 72.5 (4.9) | 0.92 |
MAP prescribed (mean [SD]) | 64.7 (3.1) | 65.3 (3.7) | 0.08 | 64.7 (3.1) | 65.1 (3.3) | 65.5 (4.5) | 0.15 |
Vasopressor use | |||||||
Vasopressor duration, hours (mean [SD]) | 48.5 (44.3) | 43.6 (40.5) | 0.24 | 48.5 (44.3) | 45.3 (41.1) | 40.3 (39.2) | 0.36 |
Vasopressor dose-rate, μg/kg/min (mean [SD]) | 0.21 (0.3) | 0.23 (0.37) | 0.53 | 0.21 (0.3) | 0.25 (0.41) | 0.2 (0.27) | 0.47 |
Vasopressor total dose, mg (mean [SD]) | 60.1 (122) | 56.6 (104.9) | 0.75 | 60.1 (121.9) | 62.9 (118.6) | 43.4 (66.5) | 0.45 |
Vasopressor(s) restarted, n (%) | 22 (11) | 36 (15.7) | 0.15 | 22 (11) | 26 (16.8) | 10 (13.5) | 0.29 |
Clinical Outcomes | |||||||
ICU Stay, days (median [IQR]) | 4.0 (2.2–8.4) | 5.0 (2.6–9.0) | 0.43 | 4.0 (2.2–8.4) | 5.1 (2.3–8.6) | 5.3 (3.0–9.8) | 0.24 |
Hospital Stay, days (median [IQR]) | 13.7 (7.3–25.4) | 12.9 (7.0–25.1) | 0.46 | 13.7 (7.3–25.4) | 12.6 (6.6–24.1) | 14.3 (8.5–28.1) | 0.47 |
ICU readmission(s), n (%) | 13 (6.5) | 20 (8.7) | 0.39 | 13 (6.5) | 11 (7.1) | 9 (12.2) | 0.28 |
Patients with ≥1 complication, n (%) | 88 (44.0) | 98 (42.8) | 0.80 | 88 (44.0) | 73 (47.1) | 25 (33.8) | 0.16 |
Mortality (ICU), n (%) | 52 (26.0) | 66 (28.8) | 0.51 | 52 (26.0) | 46 (29.7) | 20 (27.0) | 0.74 |
Mortality (Hospital), n (%) | 75 (37.5) | 78 (34.1) | 0.46 | 75 (37.5) | 54 (34.8) | 24 (32.4) | 0.71 |